Eikon Therapeutics EIKN 深 滬
已收盤 08-07 16:00:00 美东时间
9.29
+0.080
+0.87%
華盛通- 最 高9.87
- 今 開9.45
- 成交量 66.27万股
- 最 低 9.24
- 昨 收 9.21
- 總市值 5.03亿
- 52周最高 17.40
- 市盈率 靜 --
- 換手率 1.22%
- 52周最低 7.90
- 委 比 37.11%
- 總股本 5413.86万
- 歷史最高 17.40
- 量 比 2.17
- 振 幅 6.84%
- 歷史最低 7.90
- 每 手 1
- 風險率 2.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Eikon Therapeutics shares are trading higher. The company announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 study of EIK1001 with pembrolizumab and chemotherapy in stage 4 Non-Small Cell Lung Cancer.
Eikon Therapeutics shares are trading higher. The company announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 study of EIK1001 with pembrolizumab and chemotherapy in stage 4 Non-Small Cell Lung Cancer.
07-27 22:19
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
Eupraxia Pharmaceuticals Inc. announced updates to its executive leadership and operational structure to prepare for its next stage of clinical and commercial development. Dr. Jeff Millard joined as Executive Vice President, Technical Operations, bringing 25 years of experience in technical operations, CMC, and regulatory strategy. Dr. Alex Therien was appointed Executive Vice President, Research & Development, with over 20 years of biopharmaceut...
07-13 20:05
Eikon Therapeutics Set To Join Russell 3000 Index, Effective June
Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that it will be added to the broad-market Russell 3000® Index following the annual reconstitution, ef...
06-26 04:15
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Zebra Technologies, Vishay Precision Group, Quantum Computing, Aramark And Other Big Stocks Moving Higher On Tuesday
ZBRA, VSTS, AMBQ, VPG, BAK, PACS, LOT, EIKN, DDD, WEN, SIBN post significant gains on better-than-expected financial results and guidance. Peltz may take Wendy's private.
05-13 01:24
Eikon Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.
Eikon Therapeutics shares are trading higher after the company reported better-...
05-12 21:15
Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $5
Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and lowers the price target from $7 to $5.
05-12 20:39
Eikon Therapeutics Q1 EPS $(2.46) Beats $(4.07) Estimate
Eikon Therapeutics (NASDAQ:EIKN) reported quarterly losses of $(2.46) per share which beat the analyst consensus estimate of $(4.07) by 39.56 percent. This is a 90.86 percent increase over losses of $(26.91) per share
05-12 04:19
Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations, shares fall 3.8%. Other stocks also decline.
04-27 20:02
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
